WebJun 2, 2024 · PDF. Background: Eftilagimod alpha (efti) is a soluble LAG-3 protein targeting a subset of MHC class II molecules that mediate antigen presenting cell (APC) and CD8 … WebEftilagimod alpha is a large-molecule cancer drug being developed by the clinical-stage biotechnology company Immutep. Efti is a soluble version of the immune checkpoint molecule LAG-3. It is an APC Activator used to increase an immune response to tumors, and is administered by subcutaneous injection.
Study in Metastatic Breast Cancer Patients Receiving Eftilagimod …
WebThe MHC class II agonist eftilagimod alpha (efti, IMP321 or LAG-3Ig) is a soluble LAG-3 protein that activates APC leading to CD8 T-cell activation. 6–8 Efti binds to a subset of … WebMay 26, 2024 · Pembrolizumab binds to the PD-1 receptor, blocking both immune-suppressing ligands, PD-L1 and PD-L2, from interacting with PD-1 to help restore effector T-cell responses. The rationale to combine efti and pembrolizumab comes from their complementary mechanisms of action. 16省超声刀带量采购
(PDF) 790 A phase II study (TACTI-002) of eftilagimod
Web3 Candidate Eftilagimod Alpha (Efti) in Soft Tissue Sarcoma • Expansion of the efti clinical development pipeline with a new Phase II setting • Efti Phase II trial awarded €1.5M (~A$2.2M) in funding as part of the Polish Medical Research Agency ... Efti’s novel mechanism of action offers potential to enhance anti- WebFeb 8, 2016 · Phase 1 Study of IMP321 (Eftilagimod Alpha) Adjuvant to Anti-PD-1 Therapy in Unresectable or Metastatic Melanoma (TACTI-mel) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. WebJan 11, 2024 · Mechanism of action of eftilagimod alpha for the treatment of breast cancer VJOncology 6.1K subscribers Subscribe 3 256 views 9 months ago Eftilagimod alpha (IMP321) is currently being... 16省市